Items tagged with Access
Mylan secures DCGI approval in India for pretomanid, a treatment for highly drug-resistant forms of TB (post)
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years
Approval comes as a result of Mylan’s global collaboration with non-profit drug development partner TB Alliance
TB Alliance announces European Commission authorisation of new treatment for highly drug-resistant TB (post)
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
Penn Medicine-led research suggests greater access to specific HIV and TB medications is needed worldwide (post)
A specific combination of HIV and TB treatments, difficult to obtain in certain parts of the world, decreased mortality risk for patients with HIV and multidrug-resistant TB.
International coronavirus 'lockdown' encroaches on TB epidemic control (post)
Though it may be associated with the past in popular culture, tuberculosis (TB) is still the world’s most fatal infectious disease, killing an estimated 1.5 million people each year.
TB Alliance with the support of the Republic of Korea announce initiative to broaden adoption and scale up of new treatments for drug-resistant TB (post)
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder about 1 in 5 TB case.
Funded by Stop TB Partnership TB REACH: People with TB in Ukraine are the first to receive groundbreaking new BPal drug regimen (post)
23 November 2020, KIEV, UKRAINE / THE HAGUE, NETHERLANDS: Ukraine is the first country in the world, under programmatic conditions, to provide tuberculosis (TB) patients with the groundbreaking new BPaL treatment. This three-drug treatment is meant for patients with extensively drug-resistant TB (XDR-TB) and is expected to have a higher success rate than previous treatments, doing away with painful daily injections. This deadly infectious disease currently ranks as the third cause of death in Ukraine among communicable, maternal, neonatal and nutritional diseases.
J&J can sell TB drug to minors after govt panel waives local trials (post)
New Delhi: A Government of India drugs advisory committee has approved the use of Johnson & Johnson’s (J&J) bedaquiline – used to treat tuberculosis (TB) – for minor patients in the country without conducting any local clinical trials first.
UNACCEPTABLE: Ten years since the introduction of a TB rapid molecular test – but still only one in seven people in need of a rapid test have access (post)
Geneva, Switzerland, 11 December 2020 - Only one in seven people in need of being tested for tuberculosis (TB) receive a rapid diagnostic test despite the fact that the first rapid molecular test for TB has now been in existence for a decade. As the GeneXpert test marks its 10th anniversary this week, the Stop TB Partnership calls for an emergency expansion of the use of rapid molecular diagnostics to ensure the speedy and efficient diagnosis of TB for all those that need it.
MPP sublicenses sutezolid, an investigational drug for TB treatment, paving the way for clinical development (post)
The Medicines Patent Pool (MPP) and the Bill & Melinda Gates Medical Research Institute signed an agreement to advance the development of investigational sutezolid-containing TB drug regimens, especially for low- and middle-income countries, where most people with TB live. The drug candidate sutezolid, in combination with other drugs, could potentially be used as an all-oral, shortened regimen for all forms of TB, including multidrug-resistant TB.
Patients in South Africa to access six-month, all-oral treatment for highly drug-resistant TB (post)
Pretoria, 10 December 2020 — TB Alliance welcomes the Wits Health Consortium and the South African National Department of Health (DoH)’s announcement of an initiative to provide a new, shorter treatment regimen for people affected with highly drug-resistant forms of tuberculosis (TB). Funded by the United States Agency for International Development, a new clinical access program (CAP) will enroll 400 people in South Africa for treatment with a three-drug, six-month, all-oral regimen of bedaquiline, pretomanid and linezolid (known as the BPaL regimen) that has been shown to demonstrate a favorable outcome in 90% of patients.1 This treatment was developed by TB Alliance and studied in its pivotal Nix-TB trial, which was also conducted in South Africa.
Page 43 of 83 · Total posts: 0
←First 42 43 44 Last→